From: Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran
Strategy name
Total costs ($)
Total QALYs
ICER (Cost per QALY)
Incremental costs ($)
Incremental QALYs
MPH
695
0.557
0
LDX
750
0.765
264.28
54.9
0.208